Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Biogen's EPS for the twelve months ending Sep 30, 2026 was $2.34, down 78.7% year over year. For fiscal 2025 it was $8.79, down 21.4% from the year before. Over ten years it grew -5.4% a year on average. The highest annual figure on record is $31.42 in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.79 | -21.4% |
| FY2024 | Dec 31, 2024 | $11.18 | +40.3% |
| FY2023 | Dec 31, 2023 | $7.97 | -61.8% |
| FY2022 | Dec 31, 2022 | $20.87 | +100.7% |
| FY2021 | Dec 31, 2021 | $10.40 | -58.1% |
| FY2020 | Dec 31, 2020 | $24.80 | -21.1% |
| FY2019 | Dec 31, 2019 | $31.42 | +45.6% |
| FY2018 | Dec 31, 2018 | $21.58 | +81.0% |
| FY2017 | Dec 31, 2017 | $11.92 | -29.6% |
| FY2016 | Dec 31, 2016 | $16.93 | +10.4% |
| FY2015 | Dec 31, 2015 | $15.34 | +24.0% |
| FY2014 | Dec 31, 2014 | $12.37 | +58.4% |
| FY2013 | Dec 31, 2013 | $7.81 | +35.6% |
| FY2012 | Dec 31, 2012 | $5.76 | +14.3% |
| FY2011 | Dec 31, 2011 | $5.04 | +27.9% |
| FY2010 | Dec 31, 2010 | $3.94 | +17.6% |
| FY2009 | Dec 31, 2009 | $3.35 | +26.4% |
| FY2008 | Dec 31, 2008 | $2.65 | +33.2% |
| FY2007 | Dec 31, 2007 | $1.99 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.14 | -104.4% |
| Q2 FY2026 | Jun 30, 2026 | $0.66 | -84.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.15 | +31.1% |
| Q4 FY2025 | Dec 31, 2025 | -$0.33 | -118.0% |
| Q3 FY2025 | Sep 30, 2025 | $3.17 | +19.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.33 | +8.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.64 | -39.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.83 | +7.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.66 | – |
| Q2 FY2024 | Jun 30, 2024 | $4.00 | -1.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.70 | +1.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.71 | -54.9% |
| Q3 FY2023 | Sep 30, 2023 | -$0.47 | -106.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.07 | -43.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.67 | +29.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.79 | +51.6% |
| Q3 FY2022 | Sep 30, 2022 | $7.84 | +253.2% |
| Q2 FY2022 | Jun 30, 2022 | $7.24 | +142.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.06 | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.50 | +7.8% |
| Q3 FY2021 | Sep 30, 2021 | $2.22 | -50.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.99 | -68.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.69 | -66.7% |
| Q4 FY2020 | Dec 31, 2020 | $2.32 | -71.3% |
| Q3 FY2020 | Sep 30, 2020 | $4.46 | -46.8% |
| Q2 FY2020 | Jun 30, 2020 | $9.59 | +22.2% |
| Q1 FY2020 | Mar 31, 2020 | $8.08 | +13.0% |
| Q4 FY2019 | Dec 31, 2019 | $8.08 | +70.8% |
| Q3 FY2019 | Sep 30, 2019 | $8.39 | +17.3% |
| Q2 FY2019 | Jun 30, 2019 | $7.85 | +87.8% |
| Q1 FY2019 | Mar 31, 2019 | $7.15 | +29.1% |
| Q4 FY2018 | Dec 31, 2018 | $4.73 | – |
| Q3 FY2018 | Sep 30, 2018 | $7.15 | +23.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.18 | +2.7% |
| Q1 FY2018 | Mar 31, 2018 | $5.54 | +60.1% |
| Q4 FY2017 | Dec 31, 2017 | -$1.40 | -146.8% |
| Q3 FY2017 | Sep 30, 2017 | $5.79 | – |
| Q2 FY2017 | Jun 30, 2017 | $4.07 | – |
| Q1 FY2017 | Mar 31, 2017 | $3.46 | – |
| Q4 FY2016 | Dec 31, 2016 | $2.99 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?